The management of antithrombotic therapy in patients candidate for implantation or replacement of cardiac implantable electronic devices;La gestione della terapia antitrombotica nel paziente candidato a impianto o sostituzione di dispositivi elettronici impiantabili cardiaci

Giornale Italiano di Cardiologia

Volumn 15, Issue 1, 2014, Pages 56-72

  Zacà, Valerio ^a   Marcucci, Rossella ^b   Parodi, Guido ^c   Limbruno, Ugo ^d   Notarstefano, Pasquale ^e   Pieragnoli, Paolo ^c   Di Cori, Andrea ^f   Bongiorni, Maria Grazia ^f   Casolo, Giancarlo ^g  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

^d MISERICORDIA HOSPITAL   (Italy)

^e IRCCS POLICLINICO SAN DONATO   (Italy)

^f UNIVERSITY HOSPITAL OF PISA   (Italy)

^g Ospedale Versilia   (Italy)

Author keywords

Anticoagulation therapy; Antiplatelet therapy; Coronary stents; Hemorrhage; Implantable cardioverter defibrillators; Pacemakers.

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; HEPARIN;

ANTICOAGULANT THERAPY; APPARENT LIFE THREATENING EVENT; BLEEDING DISORDER; CARDIAC IMPLANT; CARDIAC IMPLANTABLE ELECTRONIC DEVICE; DECISION MAKING; ELECTRONICS; HUMAN; PRACTICE GUIDELINE; REVIEW; THROMBOEMBOLISM; TREATMENT INDICATION;

ANTICOAGULANTS; CARDIAC SURGICAL PROCEDURES; DECISION MAKING; DEFIBRILLATORS, IMPLANTABLE; HEMORRHAGE; HUMANS; PACEMAKER, ARTIFICIAL; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; RISK; STENTS; THROMBOEMBOLISM;

EID: 84893559577     PISSN: 18276806     EISSN: 19726481     Source Type: Journal    
DOI: None     Document Type: Review

References (122)

1. Arribas F, Auricchio A, Wolpert C, et al. The EHRA White Book. Europace 2012;14:iii1-55.
2. Mond HG, Proclemer A. The 11th world survey of cardiac pacing and implantable cardioverter-defibrillators: calendar year 2009 - a World Society of Arrhythmia's project. Pacing Clin Electrophysiol 2011;34:1013-27.
3. Dubner S, Auricchio A, Steinberg JS, et al. ISHNE/EHRA expert consensus on remote monitoring of cardiovascular implantable electronic devices (CIEDs). Europace 2012;14:278-93.
4. Inama G, Pedrinazzi C, Landolina M, et al ANMCO Arrhythmias, Heart Failure Areas. Use of implantable cardioverter defibrillator and cardiac resynchronization therapy: an Italian survey study on 220 cardiology departments. J Cardiovasc Med 2012;13:675-83.
5. Proclemer A, Zecchin M, Lunati M, Bongiorni MG, Padeletti L. Registro Italiano Pacemaker e Defibrillatori - Bollettino Periodico 2012. G Ital Cardiol 2013;14:784-96.
6. Bongiorni MG, Di Cori A, Soldati E, et al. Iatrogenic risk of permanent pacemaker and defibrillator implantation. G Ital Cardiol 2009;10:395-406.
7. Nielsen JC, Thomsen PE, Højberg S, et al.; DANPACE Investigators. A comparison of single-lead atrial pacing with dual-chamber pacing in sick sinus syndrome. Eur Heart J 2011;32:686-96.
8. Bardy GH, Lee KL, Mark DB, et al.; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37.
9. Bogale N, Witte K, Priori S, et al.; Scientific Committee, National Coordinators and the Investigators. The European Cardiac Resynchronization Therapy Survey: comparison of outcomes between de novo cardiac resynchronization therapy implantations and upgrades. Eur J Heart Fail 2011;13:974-83.
10. Nieuwlaat R, Prins MH, Le Heuzey JY, et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J 2008;29:1181-9.
11. Moschovitis A, Cook S, Meier B. Percutaneous coronary interventions in Europe in 2006. EuroIntervention 2010;6:189-94.
12. Go AS, Mozaffarian D, Roger VL, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation 2013;127:e6-e245.
13. Daubert JC, Saxon L, Adamson PB, et al.; European Heart Rhythm Association (EHRA); European Society of Cardiology (ESC); Heart Rhythm Society; Heart Failure Society of America (HFSA); American Society of Echocardiography (ASE); American Heart Association (AHA); European Association of Echocardiography (EAE) of ESC; Heart Failure Association of ESC (HFA). 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Europace 2012;14:1236-86.
14. Lip GY, Proclemer A, Dagres N, Bongiorni MG, Lewalter T, Blomström-Lundqvist C; Scientific Initiative Committee, European Heart Rhythm Association. Periprocedural anticoagulation therapy for devices and atrial fibrillation ablation. Europace 2012;14:741-4.
15. Douketis JD, Spyropoulos AC, Spencer FA, et al.; American College of Chest Physicians. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e326S-50S.
16. Wiegand UK, LeJeune D, Boguschewski F, et al. Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: influence of patient morbidity, operation strategy, and perioperative antiplatelet/ anticoagulation therapy. Chest 2004;126:1177-86.
17. Reynolds MR, Cohen DJ, Kugelmass AD, et al. The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators. J Am Coll Cardiol 2006;47:2493-7.
18. Mahapatra S, Bybee KA, Bunch TJ, et al. Incidence and predictors of cardiac perforation after permanent pacemaker placement. Heart Rhythm 2005;2:907-11.
19. Korantzopoulos P, Letsas KP, Liu T, Fragakis N, Efremidis M, Goudevenos JA. Anticoagulation and antiplatelet therapy in implantation of electrophysiological devices. Europace 2011;13:1669-80.
20. Birnie DH, Healey JS, Wells GA,et al.; BRUISE CONTROL Investigators. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med 2013;368:2084-93.
21. Poole JE, Gleva MJ, Mela T, et al.; REPLACE Registry Investigators. Complication rates associated with pacemaker or implantable cardioverter- defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. Circulation 2010;122:1553-61.
22. Lekkerkerker JC, van Nieuwkoop C, Trines SA, et al. Risk factors and time delay associated with cardiac device infections: Leiden device registry. Heart 2009;95:715-20.
23. Cano O, Osca J, Sancho-Tello MJ, Olagüe J, Castro JE, Salvador A. Morbidity associated with three different antiplatelet regimens in patients undergoing implantation of cardiac rhythm management devices. Europace 2011;13:395-401.
24. Michaud GF, Pelosi F Jr, Noble MD, Knight BP, Morady F, Strickberger SA. A randomized trial comparing heparin initiation 6 h or 24 h after pacemaker or defibrillator implantation. J Am Coll Cardiol 2000;35:1915-8.
25. Uslan DZ, Gleva MJ, Warren DK, et al. Cardiovascular implantable electronic device replacement infections and prevention: results from the REPLACE Registry. Pacing Clin Electrophysiol 2012;35:81-7.
26. Lai CH, Chen JY, Wu HY, Wen JS, Yang YJ. Successful conservative management with positive end-expiratory pressure for massive haemothorax complicating pacemaker implantation. Resuscitation 2007;75:189-91.
27. Forleo GB, Zeitani J, Perretta T, et al. Acute left hemothorax as a late complication of an active-fixation pacemaker lead. Ann Thorac Surg 2013;95:1081-4.
28. Carlson MD, Freedman RA, Levine PA. Lead perforation: incidence in registries. Pacing Clin Electrophysiol 2008;31:13-5.
29. Hirschl DA, Jain VR, Spindola-Franco H, Gross JN, Haramati LB. Prevalence and characterization of asymptomatic pacemaker and ICD lead perforation on CT. Pacing Clin Electrophysiol 2007;30:28-32.
30. Grubb BP, Welch M, Kanjwal K, Karabin B, Kanjwal Y. An anatomic-based approach for the placement of implantable loop recorders. Pacing Clin Electrophysiol 2010;33:1149-52.
31. Bongiorni MG, Soldati E, Zucchelli G, et al. Transvenous removal of pacing and implantable cardiac defibrillating leads using single sheath mechanical dilatation and multiple venous approaches: high success rate and safety in more than 2000 leads. Eur Heart J 2008;29:2886-93.
32. Eisen GM, Baron TH, Dominitz JA, et al.; American Society for Gastrointestinal Endoscopy. Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures. Gastrointest Endosc 2002;55:775-9.
33. Baron TH, Kamath PS, McBane RD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med 2013;368:2113-24.
34. Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010;8:202-4.
35. Kutinsky IB, Jarandilla R, Jewett M, Haines DE. Risk of hematoma complications after device implant in the clopidogrel era. Circ Arrhythm Electrophysiol 2010;3:312-8.
36. Bernard ML, Shotwell M, Nietert PJ, Gold MR. Meta-analysis of bleeding complications associated with cardiac rhythm device implantation. Circ Arrhythm Electrophysiol 2012;5:468-74.
37. Mandawat A, Curtis JP, Mandawat A, Njike VY, Lampert R. Safety of pacemaker implantation in nonagenarians: an analysis of the healthcare cost and utilization project-nationwide inpatient sample. Circulation 2013;127:1453-65.
38. Tsai V, Goldstein MK, Hsia HH, Wang Y, Curtis J, Heidenreich PA; National Cardiovascular Data's ICD Registry. Influence of age on perioperative complications among patients undergoing implantable cardioverter-defibrillators for primary prevention in the United States. Circ Cardiovasc Qual Outcomes 2011;4:549-56.
39. Nowak B, Misselwitz B, Erdogan A, et al.; Expert Committee "Pacemaker", Institute of Quality Assurance Hessen. Do gender differences exist in pacemaker implantation? Results of an obligatory external quality control program. Europace 2010;12:210-5.
40. Peterson PN, Daugherty SL, Wang Y, et al.; National Cardiovascular Data Registry. Gender differences in procedure-related adverse events in patients receiving implantable cardioverter-defibrillator therapy. Circulation 2009;119:1078-84.
41. van Eck JW, van Hemel NM, Zuithof P, et al. Incidence and predictors of in-hospital events after first implantation of pacemakers. Europace 2007;9:884-9.
42. Ahmed I, Gertner E, Nelson WB, House CM, Zhu DW. Chronic kidney disease is an independent predictor of pocket hematoma after pacemaker and defibrillator implantation. J Interv Card Electrophysiol 2010;29:203-7.
43. Chow V, Ranasinghe I, Lau J, et al. Periprocedural anticoagulation and the incidence of haematoma formation after permanent pacemaker implantation in the elderly. Heart Lung Circ 2010;19:706-12.
44. Nowak B, Przibille O. Device implantation: the human factor. Europace 2010;12:15-6.
45. Pakarinen S, Oikarinen L, Toivonen L. Short-term implantation-related complications of cardiac rhythm management device therapy: a retrospective single-centre 1-year survey. Europace 2010;12:103-8.
46. Ghanbari H, Feldman D, Schmidt M, et al. Cardiac resynchronization therapy device implantation in patients with therapeutic international normalized ratios. Pacing Clin Electrophysiol 2010;33:400-6.
47. Milic DJ, Perisic ZD, Zivic SS, et al. Prevention of pocket related complications with fibrin sealant in patients undergoing pacemaker implantation who are receiving anticoagulant treatment. Europace 2005;7:374-9.
48. Ohlow MA, Lauer B, Buchter B, Schreiber M, Geller JC. Pocket related complications in 163 patients receiving anticoagulation or dual antiplatelet therapy: D-Stat Hemostat versus standard of care. Int J Cardiol 2012;159:177-80.
49. Dreger H, Grohmann A, Bondke H, Gast B, Baumann G, Melzer C. Is antiarrhythmia device implantation safe under dual antiplatelet therapy? Pacing Clin Electrophysiol 2010;33:394-9.
50. Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50 279 patients at risk for coronary artery disease. Eur Heart J 2006;27:2667-74.
51. Oscarsson A, Gupta A, Fredrikson M, et al. To continue or discontinue aspirin in the peri-operative period: a randomized, controlled clinical trial. Br J Anaesth 2010;104:305-12.
52. Maulaz AB, Bezerra DC, Michel P, Bogousslavsky J. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol 2005;62:1217-20.
53. Beving H, Zhao C, Albage A, Ivert T. Abnormally high platelet activity after discontinuation of acetylsalicylic acid treatment. Blood Coagul Fibrinolysis 1996;7:80-4.
54. Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008;299:532-9.
55. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297:159-68.
56. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors and outcome of thrombosis after successful implantation of drug eluting stents. JAMA 2005;293:2126-30.
57. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors and outcomes of premature discontinuation of thienopyridine therapy after drug eluting stent placement: results from the PREMIER registry. Circulation 2006;113:2803-9.
58. Rossini R, Capodanno D, Lettieri C, et al. Prevalence, predictors, and long-term prognosis of premature discontinuation of oral antiplatelet therapy after drug eluting stent implantation. Am J Cardiol 2011;107:186-94.
59. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drugeluting stents. N Engl J Med 2007;356:1020-9.
60. Roy P, Bonello L, Torguson R, Oet al. Temporal relation between Clopidogrel cessation and stent thrombosis after drug-eluting stent implantation. Am J Cardiol 2009;103:801-5.
61. Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007;116:745-54.
62. Schulz S, Schuster T, Mehilli J, et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J 2009;30:2714-21.
63. Kimura T, Morimoto T, Nakagawa Y, et al.; j-Cypher Registry Investigators. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 2009;119:987-95.
64. Eisenberg MJ, Richard PR, Libersan D, Filion KB. Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation 2009;119:1634-42.
65. Valgimigli M, Borghesi M, Tebaldi M, Vranckx P, Parrinello G, Ferrari R; PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY Investigators. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). Eur Heart J 2013;34:909-19.
66. Sarno G, Lagerqvist B, Fröbert O, et al. Lower risk of stent thrombosis and restenosis with unrestricted use of "new-generation" drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 2012;33:606-13.
67. Park KW, Kang SH, Velders MA, et al. Safety and efficacy of everolimus- versus sirolimus-eluting stents: a systematic review and meta-analysis of 11 randomized trials. Am Heart J 2013;165:241-50.
68. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012;379:1393-402.
69. Ferreira-González I, Marsal JR, Ribera A, et al. Double antiplatelet therapy after drug-eluting stent implantation: risk associated with discontinuation within the first year. J Am Coll Cardiol 2012;60:1333-9.
70. Stone GW, Rutledge DR, Sudhir K, et al. Stent thrombosis and dual antiplatelet interruption. Insights from the XIENCE V everolimus-eluting coronary stent system trials [abstract]. J Am Coll Cardiol 2011;58(Suppl B):B23-4.
71. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting stents: is the paradigm shifting? J Am Coll Cardiol 2013;62:1915-21.
72. Kirtane A, Silber S, Neumann FJ, et al. Therapy use and stent thrombosis following percutaneous coronary intervention with the resolute zotarolimus-eluting stent. Abstract presented at ACC, San Francisco, California, USA, 2013. J Am Coll Cardiol 2013;61(10 Suppl): doi:10.1016/S0735-1097(13) 61862-8.
73. Rossini R, Bramucci E, Castiglioni B, et al.; Società Italiana di Cardiologia Invasiva (GISE); Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO). Stent coronarico e chirurgia: la gestione perioperatoria della terapia antiaggregante nel paziente portatore di stent coronarico candidato a intervento chirurgico. G Ital Cardiol 2012;13:528-51.
74. Tompkins C, Cheng A, Dalal D, et al. Dual antiplatelet therapy and heparin "bridging" significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation. J Am Coll Cardiol 2010;55:2376-82.
75. Valgimigli M, Campo G, Monti M, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012;125:2015-26.
76. Savonitto S, Urbano M, Caracciolo M, et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of "bridging" antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth 2010;104:285-91.
77. Angiolillo DJ, Firstenberg MS, Price MJ, et al.; BRIDGE Investigators. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012;307:265-74.
78. Wiviott SD, Trenk D, Frelinger AL, et al.; PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation Thrombolysis in Myocardial Infarction 44 Trial. Circulation 2007;116:2923-32.
79. Wiviott SD, Braunwald E, McCabe C, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.
80. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSet of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET Study. Circulation 2009;120:2577-85.
81. Wallentin L, Becker RC, Budaj A, et al.; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
82. Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 2011;57:672-84.
83. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054.
84. Wysokinski WE, McBane RD, Daniels PR, et al. Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. Mayo Clin Proc 2008;83:639-45.
85. Douketis JD, Johnson JA, Turpie AG. Low-molecular weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 2004;164:1319-26.
86. Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 2012;126:1630-9.
87. Douketis JD. Contra: Bridging anticoagulation is needed during warfarin interruption when patients require elective surgery. Thromb Haemost 2012;108:210-2.
88. Spyropoulos AC. Pro: Bridging anticoagulation is needed during warfarin interruption when patients require elective surgery. Thromb Haemost 2012;108:213-6.
89. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):160S-98S.
90. Gadisseur AP, van der Meer FJ, Adriaansen HJ, Fihn SD, Rosendaal FR. Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon. Br J Haematol 2002;117:940-6.
91. Palareti G, Legnani C. Warfarin withdrawal. Pharmacokinetic pharmacodynamic considerations. Clin Pharmacokinet 1996;30:300-13.
92. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 2005;44:1227-46.
93. Friedland S, Soetikno R. Colonoscopy with polypectomy in anticoagulated patients. Gastrointest Endosc 2006;64:98-100.
94. Kovacs MJ, Kearon C, Rodger M, et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 2004;110:1658-63.
95. Larson BJ, Zumberg MS, Kitchens CS. A feasibility study of continuing dose-reduced warfarin for invasive procedures in patients with high thromboembolic risk. Chest 2005;127:922-7.
96. Steib A, Barre J, Mertes M, et al. Can oral vitamin K before elective surgery substitute for preoperative heparin bridging in patients on vitamin K antagonists? J Thromb Haemost 2010;8:499-503.
97. Pengo V, Cucchini U, Denas G, et al.; Italian Federation of Centers for the Diagnosis of Thrombosis and Management of Antithrombotic Therapies (FCSA). Standardized low molecular- weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study. Circulation 2009;119:2920-7.
98. Feng L, Li Y, Li J, Yu B. Oral anticoagulation continuation compared with heparin bridging therapy among high risk patients undergoing implantation of cardiac rhythm devices. A meta-analysis. Thromb Haemost 2012;108:1124-31.
99. Tischenko A, Gula LJ, Yee R et al. Implantation of cardiac rhytm devices without interruption of oral anticoagulation compared with perioperative bridging with low-molecular weight heparin. Am Heart J 2009;158:252-6.
100. Tolosana JM, Berne P, Mont L, et al. Preparation for pacemaker or implantable cardiac defibrillator implants in patients with high risk of thrombo-embolic events: oral anticoagulation or bridging with intravenous heparin? A prospective randomized trial. Eur Heart J 2009;30:1880-4.
101. Ahmed I, Gertner E, Nelson WB, et al. Continuing warfarin therapy is superior to interrupting warfarin with or without bridging anticoagulation therapy in patients undergoing pacemaker and defibrillator implantation. Heart Rhythm 2010;7:745-9.
102. Li HK, Chen FC, Rea RF, et al. No increase bleeding events with continuation of oral anticoagulation therapy for patients undergoing cardiac device procedure. Pacing Clin Electrophysiol 2011;34:868-74.
103. Cano O, Munoz B, Tejada D, et al. Evaluation of a new standardized protocol for the perioperative management of chronically anticoagulated patients receiving implantable cardiac arrhythmia devices. Heart Rhythm 2012;9:361-7.
104. Marquie C, De Geeter G, Klug D, et al. Post-operative use of heparin increases morbidity of pacemaker implantation. Europace 2006;8:283-7.
105. Ghanbari H, Saint Phard W, Al-Ameri H, et al. Meta-analysis of safety and efficacy of uninterrupted warfarin compared to heparin-based bridging therapy during implantation of cardiac rhythm devices. Am J Cardiol 2012;110:1482-8.
106. Cheng A, Nazarian S, Brinker JA, et al. Continuation of warfarin during pacemaker or implantable cardioverter-defibrillator implantation: a randomized clinical trial. Heart Rhythm 2011;8:536-40.
107. Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
108. Granger CB, Alexander JH, McMurray JJ, et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.
109. Patel MR, Mahaffey KW, Garg J, et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
110. Healey JS, Eikelboom J, Douketis J, et al.; RE-LY Investigators. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. Circulation 2012;126:343-8.
111. Rowley CP, Bernard ML, Brabham WW, et al. Safety of continuous anticoagulation with dabigatran during implantation of cardiac rhythm devices. Am J Cardiol 2013;111:1165-8.
112. Bongiorni MG, Di Cori A, Soldati E, et al. Intracardiac echocardiography in patients with pacing and defibrillating leads: a feasibility study. Echocardiography 2008;25:632-8.
113. Di Cori A, Bongiorni MG, Zucchelli G, et al. Transvenous extraction performance of expanded polytetrafluoroethylene covered ICD leads in comparison to traditional ICD leads in humans. Pacing Clin Electrophysiol 2010;33:1376-81.
114. Wilkoff BL, Love CJ, Byrd CL, et al.; Heart Rhythm Society; American Heart Association. Transvenous lead extraction: Heart Rhythm Society expert consensus on facilities, training, indications, and patient management: this document was endorsed by the American Heart Association (AHA). Heart Rhythm 2009;6:1085-104.
115. Smith HJ, Fearnot NE, Byrd CL, Wilkoff BL, Love CJ, Sellers TD. Five-years experience with intravascular lead extraction. US Lead Extraction Database. Pacing Clin Electrophysiol 1994;17(11 Pt 2):2016-20.
116. Byrd CL, Wilkoff BL, Love CJ, et al. Intravascular extraction of problematic or infected permanent pacemaker leads: 1994-1996. US Extraction Database, MED Institute. Pacing Clin Electrophysiol 1999;22:1348-57.
117. Wilkoff BL, Byrd CL, Love CJ, Sellers TD, VanZandt HJ. Trends in intravascular lead extraction: analysis of data from 5339 procedures in 10 years [abstract]. Pacing Clin Electrophysiol 1999;22(6 Pt 2):A207.
118. Byrd CL, Wilkoff BL, Love CJ, Sellers TD, Reiser C. Clinical study of the laser sheath for lead extraction: the total experience in the United States. Pacing Clin Electrophysiol 2002;25:804-8.
119. Di Cori A, Bongiorni MG, Zucchelli G, et al. Single-center experience in transvenous coronary sinus lead extraction: procedural outcomes and predictors for mechanical dilatation. Pacing Clin Electrophysiol 2012;35:215-22.
120. Klug D, Lacroix D, Savoye C, et al. Systemic infection related to endocarditis on pacemaker leads: clinical presentation and management. Circulation 1997;95:2098-107.
121. Bongiorni MG, Blomström-Lundqvist C, Kennergren C, et al.; Scientific Initiative Committee, European Heart Rhythm Association. Current practice in transvenous lead extraction: a European Heart Rhythm Association EP Network Survey. Europace 2012;14:783-6.
122. Bongiorni MG, Romano SL, Kennergren C, et al. ELECTRa (European Lead Extraction ConTRolled) Registry - shedding light on transvenous lead extraction real-world practice in Europe. Herzschrittmacherther Elektrophysiol 2013;24:171-5.